AMY MONDAY: Open Payments
NPI 1396044426 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,409 in 118 payments from 19 companies in 2025. Trend: 2023 $1,875 · 2024 $2,563 · 2025 $2,409
Food & beverage: $2,409
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $564 |
| Madrigal Pharmaceuticals | 13 | $405 |
| Janssen Biotech, Inc. | 15 | $290 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $211 |
| Gilead Sciences, Inc. | 6 | $173 |
| GENZYME CORPORATION | 6 | $157 |
| Aimmune Therapeutics, Inc. | 6 | $117 |
| Ipsen Biopharmaceuticals, Inc | 4 | $87 |
| Lilly USA, LLC | 4 | $79 |
| Ardelyx, Inc. | 3 | $69 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, DUPIXENT, XIFAXAN, Livdelzi, CREON, IQIRVO.
Industry payments across AL — which companies pay providers there.
